Victory Capital Management Inc. Has $1.69 Million Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Victory Capital Management Inc. boosted its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 13.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 38,253 shares of the company’s stock after buying an additional 4,546 shares during the period. Victory Capital Management Inc. owned approximately 0.07% of Vera Therapeutics worth $1,691,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. raised its position in Vera Therapeutics by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock valued at $86,000 after purchasing an additional 350 shares in the last quarter. Arizona State Retirement System grew its position in Vera Therapeutics by 14.4% during the 2nd quarter. Arizona State Retirement System now owns 9,907 shares of the company’s stock worth $358,000 after acquiring an additional 1,250 shares during the last quarter. Ensign Peak Advisors Inc increased its position in Vera Therapeutics by 13.5% during the 2nd quarter. Ensign Peak Advisors Inc now owns 11,750 shares of the company’s stock valued at $425,000 after purchasing an additional 1,400 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Vera Therapeutics by 30.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,527 shares of the company’s stock valued at $272,000 after purchasing an additional 1,737 shares during the period. Finally, Handelsbanken Fonder AB grew its position in shares of Vera Therapeutics by 19.0% during the 3rd quarter. Handelsbanken Fonder AB now owns 13,800 shares of the company’s stock worth $610,000 after buying an additional 2,200 shares during the period. 99.21% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on VERA. Scotiabank initiated coverage on Vera Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $60.00 target price for the company. Wedbush lifted their price objective on shares of Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. Guggenheim boosted their target price on Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research note on Monday, October 28th. Wells Fargo & Company started coverage on Vera Therapeutics in a research note on Thursday. They set an “overweight” rating and a $70.00 target price on the stock. Finally, JPMorgan Chase & Co. raised their target price on Vera Therapeutics from $72.00 to $75.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $59.22.

Insider Transactions at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 15,625 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $37.50, for a total transaction of $585,937.50. Following the completion of the sale, the chief executive officer now owns 307,972 shares of the company’s stock, valued at $11,548,950. This trade represents a 4.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Beth C. Seidenberg sold 15,000 shares of Vera Therapeutics stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $48.03, for a total transaction of $720,450.00. Following the completion of the sale, the director now owns 131,553 shares of the company’s stock, valued at $6,318,490.59. This represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 89,927 shares of company stock valued at $3,800,796. Company insiders own 21.70% of the company’s stock.

Vera Therapeutics Stock Up 2.7 %

Shares of Vera Therapeutics stock opened at $48.31 on Monday. The company’s 50 day moving average price is $43.47 and its 200-day moving average price is $39.51. Vera Therapeutics, Inc. has a 52-week low of $12.28 and a 52-week high of $51.61. The stock has a market capitalization of $3.06 billion, a price-to-earnings ratio of -18.51 and a beta of 1.03. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.21). Equities research analysts forecast that Vera Therapeutics, Inc. will post -2.85 EPS for the current year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.